11:58 AM EST - Resverlogix Corp. : announced that it has completed enrollment of its exploratory Phase 2 clinical trial in patients with pre-diabetes mellitus to examine the effects of RVX-208 and ApoA-I production on glucose metabolism. Resverlogix Corp.
shares T.RVX are trading down $0.005 at $0.47.
